Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NRSNW | 6-K | neutral | 4/10 | NeuroSense Therapeutics received a Japanese patent (No. 7857044) for its lead ALS drug candidate PrimeC, extending intel | Jun 9, 2026 |
| BAK | 6-K | mixed | 6/10 | Braskem S.A. held an Extraordinary General Meeting on June 8, 2026, approving the election of a new Board of Directors a | Jun 9, 2026 |
| VNRX | 424B5 | bearish | 7/10 | VolitionRx is conducting a best-efforts offering of up to 2,960,000 shares of common stock and warrants to purchase up t | Jun 9, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem S.A. filed its updated bylaws via Form 6-K. The filing is a routine governance document that restates the compan | Jun 9, 2026 |
| BAK | 6-K | neutral | 3/10 | Braskem S.A. filed a 6-K disclosing the detailed final voting map from its Ordinary General Meeting held on June 8, 2026 | Jun 9, 2026 |
| BAK | 6-K | neutral | 4/10 | Braskem filed a 6-K reporting the final synthetic voting map from its June 8, 2026 Ordinary General Meeting, where share | Jun 9, 2026 |
| BAK | 6-K | neutral | 3/10 | Braskem S.A. held an Extraordinary General Meeting on June 8, 2026, approving a comprehensive reformulation of its bylaw | Jun 9, 2026 |
| IRON | PRESS-RELEASE | bullish | 6/10 | Disc Medicine announced alignment with the FDA that the ongoing Phase 3 APOLLO study, if successful, can serve as the ba | Jun 9, 2026 |
| BGM | 6-K | bearish | 8/10 | BGM Group closed a private placement on June 8, 2026, issuing 200 million Class A ordinary shares and warrants for 200 m | Jun 9, 2026 |
| AUTL | 8-K | bearish | 7/10 | Autolus Therapeutics published its 2025 UK Annual Report, revealing $55.983M in first-year AUCATZYL US sales, a £222.656 | Jun 9, 2026 |
| ACTU | PRESS-RELEASE | bullish | 7/10 | Actuate Therapeutics announced that its lead drug elraglusib will be evaluated in the BEACON2 platform trial for relapse | Jun 9, 2026 |
| AWHL | 8-K | bearish | 6/10 | Aspira Women's Health raised approximately $1.485 million in a private placement, issuing 3.3M shares of common stock at | Jun 9, 2026 |
| IXHL | 8-K | neutral | 3/10 | Incannex Healthcare announced that Alliance Global Partners (AGP) has initiated equity research coverage with a BUY rati | Jun 9, 2026 |
| LSTA | 8-K | bearish | 6/10 | Lisata Therapeutics entered into an amendment and waiver to its existing merger agreement with Kuva Labs, extending the | Jun 9, 2026 |
| ZEOX | 8-K | neutral | 2/10 | Zeo ScientifiX announced the expansion of its Medical Advisory Board with nine new physicians and scientists in regenera | Jun 9, 2026 |
| ATHE | PRESS-RELEASE | bullish | 7/10 | Alterity Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, achieving alignment on the pivotal Pha | Jun 9, 2026 |
| NUVL | 8-K | bullish | 8/10 | GSK plc has agreed to acquire Nuvalent for $124.00 per share in cash, representing a total equity value of $10.6 billion | Jun 9, 2026 |
| IVVD | PRESS-RELEASE | neutral | 4/10 | Invivyd dosed first participants in the LIBERTY Phase 3 trial evaluating VYD2311 (mAb) vs. mRNA COVID-19 vaccine, with t | Jun 9, 2026 |
| RDHL | 6-K | bullish | 5/10 | RedHill Biopharma announced that the FDA granted Rare Pediatric Disease (RPD) designation to opaganib for neuroblastoma, | Jun 9, 2026 |
| COCP | 8-K | neutral | 2/10 | Cocrystal Pharma appointed James Sapirstein as CEO, replacing co-CEOs Sam Lee and James Martin, who remain as President/ | Jun 9, 2026 |
| GSK | COURT-RULING | bullish | 6/10 | The District Court for the Eastern District of Pennsylvania granted GSK's motion to dismiss a securities fraud class act | Jun 9, 2026 |
| GLAXF | 6-K | bullish | 7/10 | GSK plc announced a definitive agreement to acquire Nuvalent, Inc. for $10.6 billion ($124/share in cash), a 40% premium | Jun 9, 2026 |
| GLPGF | 6-K | neutral | 3/10 | Lakefront Biotherapeutics appointed Eric Hedrick, MD, as Chief Medical Officer, effective June 8, 2026. Dr. Hedrick, who | Jun 9, 2026 |
| TKPHF | 6-K | neutral | 3/10 | Takeda announced the issuance of 16,989,076 ordinary shares (10,892,917 new shares and 6,096,159 treasury shares) at ¥5, | Jun 9, 2026 |
| PRNAF | 6-K | bullish | 7/10 | Alterity Therapeutics announced successful alignment with the FDA on the pivotal Phase 3 program for ATH434 in Multiple | Jun 9, 2026 |
| ELOX | EFFECT | neutral | 5/10 | Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-295651) became effective on June 8, 2026, clearing the w | Jun 9, 2026 |
| LODE | 8-K | neutral | 3/10 | Comstock Inc. filed an 8-K reporting that its independent auditor, Assure CPA, LLC, ceased operations and resigned after | Jun 9, 2026 |
| CGEN | EFFECT | neutral | 3/10 | Compugen's shelf registration statement on Form F-3 (File No. 333-295989) was declared effective by the SEC on June 8, 2 | Jun 9, 2026 |
| BIOF | 8-K | neutral | 4/10 | Blue Biofuels, Inc. filed an 8-K reporting that its independent auditor, Assure CPA, LLC, resigned after merging into Sa | Jun 9, 2026 |
| OCS | PRESS-RELEASE | neutral | 5/10 | Oculis announced the first patient randomized in PREDICT-1, a genotype-based registrational trial for Licaminlimab in dr | Jun 9, 2026 |